Back to mobile site

Nasus Pharma (NSRX) Reiterated at Market Outperform by Citizens

June 11, 2026 5:15 AM EDT Send to a Friend
Citizens analyst Jason Butler reiterated a Market Outperform rating and $18.00 price target on Nasus Pharma Ltd (NYSE: NSRX).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login